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It is well known in the literature that nitrogen and oxygen con-
taining compounds are essentially used inmedicine for the treat-
ment of different kinds of fungal and bacterial infections along
with the treatment of gastric ulcer, cancer, etc. (Bishayee et al.,
1997). The organic moiety having nitrogen atom results towards
higher efﬁciency against various diseases (Chitamber and
Wereley, 1997). Five membered heterocyclic compounds show
various types of biological activities. 2,5-Disubstituted 1,3,4-
oxadiazoles also display a wide spectrum of activities such as5 2660470.
om (V. Modi).
y. Production and hosting by
Saud University.
lsevier
ND license.antibacterial (Jain et al., 2009), antimalarial (Hutt et al.,
1970), anti-inﬂammatory (Silvestrini and Pagatti, 1961), anti-
fungal (Sharma and Bahel, 1982) and anticonvulsant (Omar
et al., 1984).
Substituted 1,3,4-oxadiazoles are of considerable pharma-
ceutical and material interest, which is documented by a stea-
dily increasing number of publications and patents. For
instance, 2-amino-1,3,4-oxadiazoles act as muscle relaxants
(Yale and Losee, 1966) and show antimitotic activity analge-
sic, antiinﬂammatory, anticonvulsive, diuretic and antiemetic
properties are exhibited by 5-aryl-2-hydroxymethyl-1,3,4-oxa-
diazole derivatives (Adelstein et al., 1976). Some material
applications of 1,3,4-oxadiazole derivatives lie in the ﬁelds of
photosensitizers (Chem Abst, 1983) and liquid crystals (Praja-
pati and Modi, 2010a,b, 2011). Common synthetic approaches
to oxadiazoles (Bentiss and Lagrene´e, 1999) involve cyclization
of diacylhydrazines. A variety of reaction conditions inﬂuence
the cyclization reaction. Typically, the reaction is promoted by
heat and anhydrous reagents including thionyl chloride
(Al-Talib et al., 1990), phosphorous oxychloride (Theocharis
and Alexandrou, 1990), phosphorous pentoxide (Carlsen
and Jorgensen, 1994), triphenylphosphine (Brown et al.,
1997), Lawesson’s reagent (Prajapati and Modi, 2011) and
triﬂic anhydride (Liras et al., 2000). Alternative synthetic
methods comprise the reaction of carboxylic hydrazides with
328 V. Modi, P. Modiketeneylidene triphenylphosphorane (Lo¨fﬂer and Schobert,
1997) or base-promoted cyclization reaction of trichloroacetic
acid hydrazones (Kaim et al., 1998).
Microwave activation as a non-conventional energy source
has become an important method that can be used to carry out
a wide range of reactions within short time and with high
yields than those obtained by using conventional heating.
The reactions which are not possible under conventional con-
ditions can sometimes be affected by the high energy of MWI
(Varma, 1999).
Oxadiazole, a heterocyclic nucleus has attracted wide atten-
tion of the chemists in search of new therapeutic molecules.
Out of its four possible isomers, 1,3,4-oxadiazole is widely
exploited for various applications. The therapeutic importance
of these rings prompted us to develop selective molecules in
which a substituent is capable of displaying higher pharmaco-
logical activities. In this paper, we have reported the synthesis
of oxadiazole derivatives by the conventional method and the
microwave method to ﬁnd out an effective method. Synthe-
sized compounds are also screened for microbial and cytotoxic
activities.
2. Materials and methods
2.1. Materials
The requisite starting materials such as hydrazine hydrate, eth-
anol, carbon disulﬁde, potassium hydroxide, 1-bromo tetrade-
cane, triethyl amine, 4-nitro phenylbenzoate, 4-nitrobenzoyl
chloride, (S)-ethyl lactate and (R)-2-octanol, hexane, ethyl ace-
tate, etc. were procured from Aldrich Company and used with-
out any further puriﬁcation. All the solvents were puriﬁed and
dried by standard methods. Analytical TLC was conducted on
Merck aluminium plates with 0.2 mm of silica gel 60 F-254.
Microwave synthesis was carried out by using Samsung
GW71B domestic equipment.
2.2. Methods
(R)-2-Octanol and (S)-2-n-octyloxypropanol were chosen to
prepare the chiral 4-alkoxybenzoyl chlorides. The synthesis
of the chiral 4-alkoxybenzoyl chlorides was achieved by a
Mitsunobu reaction starting from methyl 4-hydroxybenzoate
and the corresponding chiral alcohols. The resulting esters
were saponiﬁed leading to the formation of the corresponding
chiral acids, followed by the reaction with oxalyl chloride.
Hydrazide (II) was synthesized by condensing ethyl 4-nitro-
benzoate and hydrazine hydrate (80%).
2.2.1. Conventional method
2.2.1.1. 5-(4-Nitro)phenyl-3H-1,3,4-oxadiazoline-2-thione
(III) (Aurangzeb et al., 2011). A solution of KOH (1.6 g) in
water (10 ml) was added dropwise to a stirred suspension of
hydrazide (II) (28 mmol, 5.13 g) in ethanol (80 ml) at 25 C.
After all of the hydrazide has dissolved, carbon disulﬁde
(35 mmol, 2.7 g, 2.1 ml) was added at the same temperature.
The solution was evaporated in vacuum using a rotatory evap-
orator. The residue was poured into a mixture of 400 g ice and
100 ml concentrated hydrochloride acid. The precipitate
formed was ﬁltered off, and crystallized from ethanol/water
(4/1) yielding thione (III). Yield 50%.2.2.1.2. 5-(4-Nitro)phenyl-2-n-tetradecylthio-1,3,4-oxadiazole
(IV) (Aurangzeb et al., 2011). Triethylamine (3.67 mmol,
0.37 g) and 1-bromo tetradecane (3.67 mmol, 1.02 g) were suc-
cessively added dropwise to a stirred solution of (III)
(3.67 mmol, 0.80 g) in absolute ethanol (10 ml). After heating
the mixture for 6 h under reﬂux, the solvent was evaporated
on a rotatory evaporator. The residue was poured into
100 ml of water, the resulting precipitate was collected and
crystallized from ethanol/ water (1/1) yielding compound IV.
Yield 67%.
2.2.1.3. 5-(4-Aminophenyl)-2-n-tetradecylthio-1,3,4-oxadiazole
(V). A mixture of IV (2.5 mmol), stannous chloride
(14.9 mmol) and absolute ethanol (10 ml) was heated gently
at reﬂux for 4 h. The resulting solution was allowed to cool
to room temperature and neutralized with 10% aqueous so-
dium hydroxide to pH 7. The precipitate formed was ﬁltered
and dried in a vacuum oven for 12 h. The dried solid was stir-
red with chloroform for 2 h and the insoluble solid was ﬁltered
off. The solid obtained after evaporation of the chloroform
was recrystallised from ethanol. Yield 65%.
Amides Ia–hwere synthesized by the condensation of amino-
oxadiazole (V) with 4-n-alkoxybenzoyl chloride (chiral amides
were prepared by the corresponding chiral alkoxybenzoyl chlo-
rides derived from (R)-2-octanol and (S)-ethyl lactate). The
products were puriﬁed by column chromatography using the
mixture of ethyl acetate and hexane as an eluant. Products were
crystallized by mixture of ethanol/water (2/1). The following
yields were obtained: Ia (85%), Ib (72%), Ic (75%), Id (79%),
Ie (78%), If (85%), Ig (77%), Ih (65%).
2.2.2. Microwave method
2.2.2.1. 5-(4-Nitro)phenyl-2-n-tetradecylthio-1,3,4-oxadiazole
(IV). Triethylamine (0.36 mmol) and 1-bromo tetradecane
(0.36 mmol were successively added dropwise to a stirred solu-
tion of (III) (0.36 mmol) in absolute ethanol (1 ml). Reaction
mixture was kept under microwave for 55 s at 760 W. The sol-
vent was evaporated on a rotatory evaporator. The residue
was poured into 100 ml of water, the resulting precipitate
was collected and crystallized from ethanol/ water (1/1) yield-
ing the compound IV. Yield 85%.
2.2.2.2. 5-(4-Aminophenyl)-2-n-tetradecylthio-1,3,4-oxadiazole
(V). A mixture of IV (0.25 mmol), stannous chloride
(1.49 mmol) and absolute ethanol (1 ml) was kept under micro-
wave for 70 s. The resulting solution was allowed to cool to
room temperature and neutralized with 10% aqueous sodium
hydroxide to pH7. The precipitate formedwas ﬁltered and dried
in a vacuum oven. The dried solid was stirred with chloroform
for 2 h and the insoluble solidwas ﬁltered off. The solid obtained
after evaporation of the chloroformwas recrystallised from eth-
anol. Yield 85%.
Amides Ia–hwere synthesized by themixing of amino-oxadi-
azole (V) (0.01 mol) with 4-n-alkoxybenzoyl chloride (0.01 mol)
(chiral amides were prepared by the corresponding chiral alkox-
ybenzoyl chlorides derived from (R)-2-octanol and (S)-ethyl lac-
tate) in 1 ml pyridine. The resulting mixture was kept under
microwave for 40 s. (1:1) cold HCl was added to the reaction
mixture and ﬁltered. The obtained products, after drying, were
puriﬁed by column chromatography using the mixture of ethyl
acetate and hexane as an eluant. Products were crystallized by
the mixture of ethanol/water (2/1). The following yields were
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(92%), Ig (88%), Ih (86%).2.3. Characterization
The structures of the compounds were conﬁrmed by 1H and
13C nuclear magnetic resonance (NMR; Bruker AC-250P)
spectra and Fourier transform infrared (FTIR; Nicolet 550)
spectra; the purity of the ﬁnal products was evaluated by thin
layer chromatography (TLC).
2.3.1. Spectroscopic characterization of compound (III)
1H NMR (DMSO-d6, TMS, 250 MHz): d ppm= 8.15 (d,
J= 6.9 Hz, 2H, arom. H); 8.50 (d, J= 6.9 Hz, 2H, arom.
H); 12.39–16.78 (s broad, 1H, NH). 13C NMR (DMSO-d6,
TMS, 62.9 MHz): d ppm= 124.6, 127.4 (arom. C); 128.0,
149.1, 158.9, 177.8 (quaternary arom. C). FTIR (KBr disc):
cm1 = 3082 (Csp2–H); 1580 (C‚C); 1524 (C‚N); 1345
(C‚S). Elemental analysis: Calculated for C8H5N3O3S: C,
43.04; H, 2.24; N, 18.83%. Found: C, 43.01; H, 2.20; N,
18.75%. Melting point 202 C.
2.3.2. Spectroscopic characterization of compound (IV)
1H NMR (CDCl3, TMS, 250 MHz): d ppm = 0.85 (t,
J= 6.8 Hz, 3H, CH3); 1.20 (m, 22H, 11CH2); 1.81 (m, 2H,
SCH2–CH2); 3.30 (t, J= 7.4 Hz, 2H, SCH2); 8.21 (d,
J= 7.0 Hz, 2H, arom. H); 8.31 (d, J= 7.0 Hz, 2H, arom.
H). 13C NMR (CDCl3, TMS, 62.9 MHz): d ppm 14.4, 15.1,
15.3, 15.5, 16.7, 17.0, 17.7, 18.5 (aliph. C); 110.2, 113.3 (arom.
C); 115.0, 135.2, 150.0, 155.7 (quaternary arom. C). FTIR
(KBr disc): cm1 = 3089 (Csp2–H); 2919 (Csp3–H); 1600
(C‚C); 1521 (C‚N). Elemental analysis: Calculated for
C22H33N3O3S: C, 63.00; H, 7.87; N, 10.02%. Found: C,
62.97; H, 7.84; N, 10.00%. Melting point 75–76 C.
2.3.3. Spectroscopic characterization of compound (V)
1H NMR (CDCl3, TMS, 250 MHz): d ppm = 0.85 (t,
J= 6.7 Hz, 3H, CH3); 1.21 (m, 22H, 11CH2); 1.78 (m, 2H,
SCH2–CH2); 3.21 (t, J= 7.2 Hz, 2H, SCH2); 4.14 (s broad,
2H, NH2); 6.77 (d, J= 6.7 Hz, 2H, arom. H); 7.69 (d,
J= 6.7 Hz, 2H, arom. H). 13C NMR (CDCl3, TMS,
62.9 MHz): d ppm = 14.0, 22.6, 23.1, 23.5, 23.9, 24.7, 25.6,
30.8, 31.8, 32.6 (aliph. C); 113.4, 149.5 (arom. C); 114.5, 128.3,
163.0, 166.0 (quaternary arom. C). FTIR (KBr disc): cm1 =
3410, 3325 (NH2); 3210 (Csp
2–H); 2910 (Csp3–H); 1603
(C‚C). Elemental analysis: Calculated for C22H35N3OS: C,
67.86; H, 8.99; N, 10.79%. Found: C, 67.84; H, 8.95; N,
10.73%. Melting point 96 C.
2.3.4. Spectroscopic characterization of amides Ia–h
Ia: 1H NMR (CDCl3, TMS, 250 MHz): d ppm= 0.81 (t, 3H,
CH3); 0.92 (t, 3H, CH3); 1.15–1.45 (m, 24H, 12 · CH2); 1.71
(m, 4H, OCH2–CH2 and SCH2–CH2); 3.20 (t, J= 7.1 Hz,
2H, SCH2); 3.95 (t, J= 6.4 Hz, 2H, OCH2); 6.86 (d,
J= 8.3 Hz, 2H, arom. H); 7.65 (m, 4H, arom. H); 7.82 (d,
J= 8.2 Hz, 2H, arom. H); 8.16 (s, 1H, NH). 13C NMR
(CDCl3, TMS, 62.9 MHz): d ppm= 13.7, 14.0, 19.1, 22.6,
28.5, 28.9, 29.1, 9.3, 29.4, 29.6, 31.1, 31.8 (aliph. C); 32.5
(SCH2); 67.8 (OCH2); 114.3, 120.0, 127.5, 129.0 (arom. C);
118.9, 126.1, 128.3, 141.3, 162.2, 164.5 (quaternary arom. C);165.5 (C‚O). FTIR (KBr disc): cm1 = 3309 (NH); 2920
(Csp3–H); 1650 (C‚O); 1605 (C‚C). Elemental analysis: Cal-
culated for C33H47N3O3S: C, 70.08; H, 8.31; N, 7.43%. Found:
C, 70.01; H, 8.25; N, 7.41%.
Ib: 1H NMR (CDCl3, TMS, 250 MHz): d ppm = 0.82 (t,
3H, CH3); 0.94 (t, 3H, CH3); 1.18–1.45 (m, 26H, 13 · CH2);
1.73 (m, 4H, OCH2–CH2 and SCH2–CH2); 3.20 (t,
J= 7.2 Hz, 2H, SCH2); 3.93 (t, J= 6.4 Hz, 2H, OCH2);
6.89 (d, J= 8.2 Hz, 2H, arom. H); 7.79 (m, 4H, arom. H);
7.88 (d, J= 8.2 Hz, 2H, arom. H); 8.17 (s, 1H, NH). 13C
NMR (CDCl3, TMS, 62.9 MHz): d ppm= 13.8, 14.2, 19.1,
22.6, 28.6, 28.9, 29.1, 29.3, 29.5, 29.6, 31.1, 31.9 (aliph. C);
32.5 (SCH2); 67.8 (OCH2); 114.5, 120.2, 127.7, 129.2 (arom.
C); 118.9, 126.2, 128.3, 141.4, 162.2, 164.6 (quaternary arom.
C); 165.6 (C‚O). FTIR (KBr disc): cm1 = 3312 (NH);
2921 (Csp3–H); 1650 (C‚O); 1605 (C‚C). Elemental analy-
sis: Calculated for C34H49N3O3S: C, 70.46; H, 8.46; N,
7.25%. Found: C, 70.41; H, 8.43; N, 7.20%.
Ic: 1H NMR (CDCl3, TMS, 250 MHz): d ppm= 0.86 (t,
3H, CH3); 0.90 (t, 3H, CH3); 1.24–1.45 (m, 28H, 14 · CH2);
1.79 (m, 4H, OCH2–CH2 and SCH2–CH2); 3.26 (t,
J= 7.3 Hz, 2H, SCH2); 3.99 (t, J= 6.5 Hz, 2H, OCH2);
6.95 (d, J= 8.2 Hz, 2H, arom. H); 7.81 (m, 4H, arom. H);
7.98 (d, J= 7.9 Hz, 2H, arom. H); 8.12 (s, 1H, NH). 13CNMR
(CDCl3, TMS, 62.9 MHz): d ppm = 14.0, 14.1, 22.5, 22.7,
25.6, 28.6, 29.0, 29.2, 29.3, 29.4, 29.6, 31.5, 31.9 (aliph. C);
32.6 (SCH2); 68.2 (OCH2); 114.4, 119.9, 127.6, 129.0 (arom.
C); 119.0, 126.1, 128.4, 141.2, 162.3, 164.8 (quaternary arom.
C); 165.3 (C‚O). FTIR (KBr disc): cm1 = 3324 (NH);
2922 (Csp3–H); 1651 (C‚O); 1605 (C‚C). Elemental analy-
sis: Calculated for C35H51N3O3S: C, 70.82; H, 8.60; N,
7.08%. Found: C, 70.78; H, 8.56; N, 7.01%.
Id: 1H NMR (CDCl3, TMS, 250 MHz): d ppm = 0.87 (t,
6H, 2 X CH3); 1.25–1.83 (m, 34H, 17 · CH2); 3.28 (t,
J= 7.3 Hz, 2H, SCH2); 4.01 (t, J= 6.5 Hz, 2H, OCH2);
6.98 (d, J= 8.7 Hz, 2H, arom. H); 7.81 (d, J= 8.8 Hz, 2H,
arom. H); 7.86 (d, J= 8.8 Hz, 2H, arom. H); 8.00 (d,
J= 8.5 Hz, 2H, arom. H); 8.05 (s, 1H, NH). 13C NMR
(CDCl3, TMS, 62.9 MHz): d ppm = 14.1, 22.6, 22.7, 25.9,
28.6, 29.0, 29.2, 29.3, 29.4, 29.5, 29.6, 31.7, 31.9 (aliph. C);
32.6 (SCH2); 68.3 (OCH2); 114.5, 119.8, 127.6, 128.9 (arom.
C); 119.1, 126.2, 128.3, 141.2, 162.3, 164.2 (quaternary arom.
C); 165.2 (C‚O). FTIR (KBr disc): cm1 = 3315 (NH);
2921 (Csp3–H); 1648 (C‚O); 1604 (C‚C). Elemental analy-
sis: Calculated for C36H53N3O3S: C, 71.16; H, 8.73; N,
6.91%. Found: C, 71.11; H, 8.68; N, 6.89%.
Ie: 1H NMR (CDCl3, TMS, 250 MHz): d ppm= 0.89 (t,
6H, 2 X CH3); 1.23–1.80 (m, 36H, 18 · CH2); 3.25 (t,
J= 7.2 Hz, 2H, SCH2); 4.05 (t, J= 6.7 Hz, 2H, OCH2);
6.99 (d, J= 8.8 Hz, 2H, arom. H); 7.80 (d, J= 8.8 Hz, 2H,
arom. H); 7.87 (d, J= 8.6 Hz, 2H, arom. H); 7.99 (d,
J= 8.7 Hz, 2H, arom. H); 8.1 (s, 1H, NH). 13C NMR (CDCl3,
TMS, 62.9 MHz): d ppm= 14.0, 22.5, 22.7, 26.0, 28.8, 29.0,
29.1, 29.3, 29.4, 29.5, 29.6, 31.5, 31.8 (aliph. C); 32.8 (SCH2);
68.2 (OCH2); 114.5, 120.0, 127.5, 128.7 (arom. C); 119.0,
126.1, 128.2, 141.5, 162.1, 164.3 (quaternary arom. C); 165.1
(C‚O). FTIR (KBr disc): cm1 = 3314 (NH); 2920 (Csp3–
H); 1649 (C‚O); 1602 (C‚C). Elemental analysis: Calculated
for C37H55N3O3S: C, 71.49; H, 8.85; N, 6.76%. Found: C,
71.43; H, 8.83; N, 6.73.
If: 1H NMR (CDCl3, TMS, 250 MHz): d ppm= 0.90 (t,
6H, 2 · CH3); 1.25–1.80 (m, 40H, 20 · CH2); 3.26 (t,
Table 1 Microbial activity data for synthesized series I.
Sr.
No.
Anti bacterial blank 12 mm Anti fungal blank 10 mm
E. coli S. aureus A. niger A. oryzae
Ia 13.00 12.25 10.25 10.25
Ib 13.25 12.50 10.25 10.50
Ic 13.25 12.50 10.25 10.50
Id 12.25 12.25 10.00 10.25
Ie 12.25 12.25 10.00 10.25
If 12.50 12.50 10.25 10.25
Ig 12.50 12.25 10.25 10.00
Ih 12.75 12.50 10.50 10.00
Furacin (as a standard): E. coli: 14.75; S. aureus: 14.75; A. niger:
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(d, J= 8.7 Hz, 2H, arom. H); 7.82 (d, J= 8.6 Hz, 2H, arom.
H); 7.88 (d, J= 8.8 Hz, 2H, arom. H); 8.10 (d, J= 8.6 Hz,
2H, arom. H); 8.06 (s, 1H, NH). 13C NMR (CDCl3, TMS,
62.9 MHz): d ppm= 14.0, 22.4, 22.6, 26.1, 28.6, 29.0, 29.1,
29.2, 29.4, 29.6, 29.8, 31.7, 32.0 (aliph. C); 32.7 (SCH2); 68.5
(OCH2); 114.4, 120.0, 127.8, 128.9 (arom. C); 119.0, 126.1,
128.3, 141.1, 162.1, 164.2 (quaternary arom. C); 165.4
(C‚O). FTIR (KBr disc): cm1 = 3316 (NH); 2920 (Csp3–
H); 1650 (C‚O); 1606 (C‚C). Elemental analysis: Calculated
for C39H59N3O3S: C, 72.11; H, 9.09; N, 6.47%. Found: C,
72.09; H, 9.05; N, 6.43%.
Ig: 1H NMR (CDCl3, TMS, 250 MHz): d ppm= 0.86 (t,
J= 6.4 Hz, 6H, 2 · CH3); 1.28 (m, 35H, 16 · CH2 and 3H
of the methyl branch); 1.80 (m, 2H, SCH2–CH2–); 3.25 (t,
J= 7.0 Hz, 2H, SCH2); 4.42 (m, 1H, CH of the chiral tail);
6.91 (d, J= 7.8 Hz, 2H, arom. H); 7.81 (m, 4H, arom. H);
7.95 (d, J= 7.5 Hz, 2H, arom. H); 8.30 (s, 1H, NH). 13C
NMR (CDCl3, TMS, 62.9 MHz): d ppm = 13.9, 14.0, 19.3,
22.4, 22.5, 25.2, 28.4, 28.8, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5,
31.5, 31.7, 32.4, 36.0 (aliph. C); 73.8 (CH of the chiral tail);
115.20, 119.8, 127.4; 128.9 (arom. C); 118.8, 125.7, 126.2,
141.2, 161.3, 164.3 (quaternary arom. C); 165.3 (C‚O). FTIR
(KBr disc): cm1 = 3296 (NH); 2920, 2852 (Csp3–H); 1646
(C‚O); 1603 (C‚C); 1247 (C–O). Elemental analysis: Calcu-
lated for C37H54N3O3S: C, 71.61; H, 8.70; N, 6.77%. Found:
C, 71.58; H, 8.65; N, 6.72%.
Ih: 1H NMR (CDCl3, TMS, 250 MHz): d ppm= 0.80 (t,
6H, 2 · CH3); 1.17–1.96 (m, 39H, 18 · CH2 and 3H of the
methyl branch); 3.21 (t, J= 7.0 Hz, 2H, SCH2); 3.56 (t,
J= 6.6 Hz, 2H, OCH2); 3.66 (m, 1H, CH of the chiral tail);
3.92 (m, 1H, OCH2); 3.96 (m, 1H, OCH2); 7.26 (d,
J= 8.8 Hz, 2H, arom. H); 7.64 (d, J= 8.9 Hz, 2H, arom.
H); 7.90 (d, J= 8.8 Hz, 2H, arom. H); 8.37 (d, J= 8.8 Hz,
2H, arom. H); 8.95 (s, 1H, NH). 13C NMR (CDCl3, TMS,
62.9 MHz): d ppm= 14.0, 14.1, 17.2, 22.6, 28.5, 28.9, 29.0,
29.1, 29.3, 29.4, 29.6, 29.9, 31.8 (aliph. C); 32.6 (methyl
branch); 69.6, 71.6 (OCH2); 73.55 (CH of the chiral tail);
118.1, 119.8, 127.6, 128.3 (arom. C); 121.0, 128.8, 140.0,
159.2, 161.8, 164.5 (quaternary arom. C); 165.1 (C‚O). FTIR
(KBr disc): cm1 = 3347 (NH); 2919, 2849 (Csp3–H); 1699
(C‚O); 1607 (C‚C); 1298 (C–O). Elemental analysis: Calcu-
lated for C39H58N3O4S: C, 70.48; H, 8.73; N, 6.32%. Found:
C, 70.45; H, 8.70; N, 6.30%.Table 2 Cytotoxic activity of data for synthesized series I.
Sr. No. Solubility ED50 lg/ml
Ia DMSO 24.27
Ib DMSO 43.23
Ic DMSO 37.05
Id DMSO 45.93
Ie DMSO 48.34
If DMSO 46.36
Ig DMSO 47.32
Ih DMSO 39.26
Standard Podophyllotoxin 3.88
12.00; A. oryzae: 12.00 mm.
Grieseofulvin (as a standard): E. coli: 12.00; S. aureus: 12.00; A.
niger: 10.00; A. oryzae: 11.75 mm.
2.4. Biological activities
2.4.1. Antibacterial and antifungal activity (Barry, 1976)
The compoundswere tested in-vitro for their antibacterial activ-
ity against two microorganisms viz. Escherichia coli and Staph-
ylococcus aureus, which are pathogenic in human beings by cup-
plate agar diffusionmethod. The compoundswere tested in vitro
for their antifungal activity against Aspergillus oryzae and
Aspergillus niger by cup-plate agar diffusion method.
Procedure: All compounds were screened for antibacterial
activity against E. coli and S. aureus by cup plate method (Bar-
ry, 1976). For anti bacterial activity, we had taken 20 gm of lur-
ia broth (Hi media M-575) and 25 gm of agar–agar in 1000 ml
distilled water and heated till it dissolved. Then, the mixture
was sterilized by autoclaving at 15 lbs pressure and 121 C for
15 min. Here, agar–agar was used to solidify the solution. Afterthat, six Petri dishes having ﬂat bottom were taken and ﬁlled
with about 18 ml of the above solution. Overlay the plate with
4 ml soft agar–agar containing 0.1 ml test culture. Bored four
well of 8 mm diameter in each plate. We had then dissolved
the compound in DMF having 1000 ppm concentration and
added 0.1 ml of testing solution into each well. This solution
was allowed to diffuse at 4 C. After 20 min of diffusion, the
plate was incubated at 37 C overnight. After incubation, we
observed the zone of inhibition and measured the diameter of
the zone. For anti fungal activity, we had taken 20 gm Sabou-
raud dextrose instead of lubria broth and followed the same
procedure as above. All the synthesized compounds showed
good antimicrobial activity (Table 1).
2.4.2. Cytotoxicity test
2.4.2.1. Brine shrimp lethality bioassy (BSLT). Brine shrimp
lethality test has been used as a bioassay for a variety of toxic
substances. This method has also been applied to plant ex-
tracts in order to facilitate the isolation of biologically active
compounds. A general bioassay that appears capable of detect-
ing a broad spectrum of bioactivity, present in crude extracts
and in synthetic compounds is the brine shrimp lethality bioas-
say, rather than more tedious and expensive in vitro and in vivo
antitumor assays. Furthermore, it does not require animal ser-
um as is needed for cytotoxicities.
Procedure: Brine shrimp lethality bioassay was carried out
to investigate the cytotoxicity of medicinal plants. Brine
shrimps (Artemia salina) were hatched using brine shrimp eggs
in a conical shaped vessel (1L), ﬁlled with sterile artiﬁcial sea
water under constant aeration for 38 h. After hatching, active
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Scheme 1 Synthetic route for series I compounds. Reagents and conditions: (a) hydrazine hydrate, ethanol, reﬂux; (b) carbon disulﬁde,
KOH; (c) 1-bromo tetradecane, triethyl amine; (d) stannous chloride; (e) substituted alkoxy acid chloride.
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tion of the chamber and used for the assay. Ten nauplii were
drawn through a glass capillary and placed in each vial con-
taining 5 ml of the brine solution. In each experiment, test sub-
stances whose activities are to be checked were added to the
vial according to their concentrations and maintained at room
temperature for 24 h under the light and surviving larvae were
counted. Experiments were conducted along with control
(vehicle treated), different concentrations (1-5000 lg/ml) of
the test substances in a set of three tubes per dose. Replicas
should be maintained to get accurate results (Table 2).
3. Results and discussion
The synthetic route for the preparation of series I compounds
is outlined in Scheme 1. For the reaction of secondary
alcohols, there is inversion at the hydroxyl carbon indicating
that the reaction occurs by activation of the alcohol followed
by SN2 displacement by phenol. Therefore, the Mitsunobu
reaction between methyl 4-hydroxybenzoate and (R)-2-octanol
proceeded with inversion of the conﬁguration at the chiral cen-
tre, so the stereochemistry of the corresponding chiral prod-
ucts is S. On the other hand, (S)-2-n-octyloxypropanol is a
primary alcohol, and the conﬁguration at the chiral centre is
not affected in the Mitsunobu reaction, therefore the stereo-
chemistry of the compounds containing a chiral alkoxy chain
derived from this alcohol is S. The 1H NMR, 13C NMR and
FTIR spectra are fully consistent with the structure. Brine
shrimp lethality test has been used as a bioassay for a variety
of toxic substances. All the synthesized compounds (Ia–h) were
tested for cytotoxic activity by the BSLT bioassay method.
Among them compounds Ia, Ic, Ih showed a dose dependent
cytotoxic activity at concentrations of (Ia) 24.27 lg/ml, (Ic)
37.05 lg/ml, (Ih) 39.26 lg/ml, respectively. The remainingcompounds exhibited less activity when compared to the above
mentioned compounds at various concentration levels. The de-
gree of lethality is directly proportional to the concentration of
the synthesized compounds. Podophyllotoxin was used as a
standard drug for BSLT assay method.4. Conclusion
All the synthesized derivatives of series I were synthesized by
conventional and microwave methods. Synthesis of com-
pounds by the microwave method gives comparatively more
yield and requires less time to complete the reaction. So, the
microwave synthesis method is better than the conventional
method. All the synthesized compounds of series I was
screened for the microbial activity. In the present study, all
synthesized compounds showed moderated to good microbial
activities. Activity increases as the number of carbon increases
in alkyl chain. All the synthesized compounds show moderate
to good anti fungal activities. All the compounds were found
to possess cytotoxic activity.
The newly synthesized oxadiazole derivatives have good to
moderate anti-bacterial and anti-fungal activities, they may be
used for the development of new drugs for the treatment of
bacterial and fungal diseases.References
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